...
search icon
elox-img

Eloxx pharmaceuticals inc. share price

ELOX
NAQ
$16.77
+$1.7
(11.28%)
1D
Sector: Healthcare

Eloxx pharmaceuticals inc. analyst forecast

Eloxx pharmaceuticals inc. share price chart

Eloxx pharmaceuticals inc. key stock metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$51.79M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
4.7094
Volume info-icon
This is the total number of shares traded during the most recent trading day.
38.90K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-160692.25
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$8.2 L
$23.4 H
$16.77

About eloxx pharmaceuticals inc., common stock

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders. more

Sector: Healthcare

Eloxx pharmaceuticals inc. stock returns

Data is not properly formatted.

Eloxx pharmaceuticals inc. financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue---6.36M-[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Cost of Revenue960.00K695.00K---[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.4,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Gross Profit(960.00K)(695.00K)-6.36M-[{"date":"2021-12-31","value":-15.1,"profit":false},{"date":"2022-12-31","value":-10.93,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Gross Margin(Infinity%)(Infinity%)-100.00%-[{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Operating Expenses41.39M33.72M17.29M8.83M6.44M[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":81.48,"profit":true},{"date":"2023-12-31","value":41.77,"profit":true},{"date":"2024-12-31","value":21.33,"profit":true},{"date":"2025-12-31","value":15.56,"profit":true}]
Operating Income(42.35M)(34.42M)(17.29M)(2.47M)(6.44M)[{"date":"2021-12-31","value":-4234800000,"profit":false},{"date":"2022-12-31","value":-3441900000,"profit":false},{"date":"2023-12-31","value":-1728800000,"profit":false},{"date":"2024-12-31","value":-246800000,"profit":false},{"date":"2025-12-31","value":-643800000,"profit":false}]
Total Non-Operating Income/Expense(25.63M)(3.40M)(665.00K)(1.79M)(573.00K)[{"date":"2021-12-31","value":-2563000000,"profit":false},{"date":"2022-12-31","value":-339800000,"profit":false},{"date":"2023-12-31","value":-66500000,"profit":false},{"date":"2024-12-31","value":-179200000,"profit":false},{"date":"2025-12-31","value":-57300000,"profit":false}]
Pre-Tax Income(66.73M)(36.14M)(17.05M)(3.14M)(6.00M)[{"date":"2021-12-31","value":-6672700000,"profit":false},{"date":"2022-12-31","value":-3614200000,"profit":false},{"date":"2023-12-31","value":-1705400000,"profit":false},{"date":"2024-12-31","value":-314300000,"profit":false},{"date":"2025-12-31","value":-599500000,"profit":false}]
Income Taxes-(77.00K)---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income After Taxes(66.73M)(36.06M)(17.05M)(3.14M)(6.00M)[{"date":"2021-12-31","value":-6672700000,"profit":false},{"date":"2022-12-31","value":-3606500000,"profit":false},{"date":"2023-12-31","value":-1705400000,"profit":false},{"date":"2024-12-31","value":-314300000,"profit":false},{"date":"2025-12-31","value":-599500000,"profit":false}]
Income From Continuous Operations(66.73M)(36.06M)(17.05M)(3.14M)(6.00M)[{"date":"2021-12-31","value":-6672700000,"profit":false},{"date":"2022-12-31","value":-3606500000,"profit":false},{"date":"2023-12-31","value":-1705400000,"profit":false},{"date":"2024-12-31","value":-314300000,"profit":false},{"date":"2025-12-31","value":-599500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(66.73M)(36.06M)(17.05M)(3.14M)(6.00M)[{"date":"2021-12-31","value":-6672700000,"profit":false},{"date":"2022-12-31","value":-3606500000,"profit":false},{"date":"2023-12-31","value":-1705400000,"profit":false},{"date":"2024-12-31","value":-314300000,"profit":false},{"date":"2025-12-31","value":-599500000,"profit":false}]
EPS (Diluted)(419.65)(183.13)(72.93)(9.24)(5.34)[{"date":"2021-12-31","value":-41965,"profit":false},{"date":"2022-12-31","value":-18313,"profit":false},{"date":"2023-12-31","value":-7293,"profit":false},{"date":"2024-12-31","value":-924,"profit":false},{"date":"2025-12-31","value":-534,"profit":false}]

Eloxx pharmaceuticals inc. ratios

Eloxx pharmaceuticals inc. liquidity ratios

These ratios help you determine the liquidity of the company. Higher is better.

ELOX
Cash Ratio 3.65
Current Ratio 3.74
Quick Ratio 3.74

Eloxx pharmaceuticals inc. asset efficiency ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ELOX
ROA (LTM) -13.02%
ROE (LTM) -42.52%

Eloxx pharmaceuticals inc. liability ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ELOX
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.73

Eloxx pharmaceuticals inc. valuation ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ELOX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.45
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.53

Faqs

What is Eloxx Pharmaceuticals Inc. share price today?

Eloxx Pharmaceuticals Inc. (ELOX) share price today is $16.77

Can Indians buy Eloxx Pharmaceuticals Inc. shares?

Yes, Indians can buy shares of Eloxx Pharmaceuticals Inc. (ELOX) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ELOX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Eloxx Pharmaceuticals Inc. be purchased?

Yes, you can purchase fractional shares of Eloxx Pharmaceuticals Inc. (ELOX) via the Vested app. You can start investing in Eloxx Pharmaceuticals Inc. (ELOX) with a minimum investment of $1.

How to invest in Eloxx Pharmaceuticals Inc. shares from India?

You can invest in shares of Eloxx Pharmaceuticals Inc. (ELOX) via Vested in three simple steps:

  • Click on Sign Up or Invest in ELOX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Eloxx Pharmaceuticals Inc. shares

What is Eloxx Pharmaceuticals Inc. 52-week high and low stock price?

The 52-week high price of Eloxx Pharmaceuticals Inc. (ELOX) is $23.4. The 52-week low price of Eloxx Pharmaceuticals Inc. (ELOX) is $8.2.

What is Eloxx Pharmaceuticals Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Eloxx Pharmaceuticals Inc. (ELOX) is 4.7094

What is Eloxx Pharmaceuticals Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Eloxx Pharmaceuticals Inc. (ELOX) is 2.45

What is Eloxx Pharmaceuticals Inc. dividend yield?

The dividend yield of Eloxx Pharmaceuticals Inc. (ELOX) is 0.00%

What is the Market Cap of Eloxx Pharmaceuticals Inc.?

The market capitalization of Eloxx Pharmaceuticals Inc. (ELOX) is $51.79M

What is Eloxx Pharmaceuticals Inc.'s stock symbol?

The stock symbol (or ticker) of Eloxx Pharmaceuticals Inc. is ELOX

How Can Investors Use Eloxx Pharmaceuticals Inc. Share Price Data for Long-Term Investment Decisions?

Consider the share price of Eloxx Pharmaceuticals Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Eloxx Pharmaceuticals Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Eloxx Pharmaceuticals Inc. shares for Indian investors?

When investing in Eloxx Pharmaceuticals Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Eloxx Pharmaceuticals Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Eloxx Pharmaceuticals Inc. share price with other stocks in the same sector?

Rather than merely checking the share price of Eloxx Pharmaceuticals Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Eloxx Pharmaceuticals Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top